CellOrigin Biotechnology

CellOrigin Biotechnology is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of genetically engineered induced pluripotent stem cell (iPSC)-derived immune cell therapies. The company’s core focus is on creating "off-the-shelf" allogeneic therapies, specifically Chimeric Antigen Receptor Macrophages (CAR-iMAC) and Natural Killer (NK) cells, to treat advanced solid tumors and hematological malignancies. CellOrigin leverages a proprietary technology platform that integrates single-cell sequencing, synthetic biology, and gene editing to optimize the differentiation and functionality of its cell products. Its lead program, SY001, is a mesothelin-targeting CAR-iMAC therapy currently undergoing Phase 1 clinical trials for patients with advanced solid tumors, including ovarian and pancreatic cancers. The company has established a global strategic partnership with Qilu Pharmaceutical for the co-development and commercialization of its CAR-iMAC products and operates its own cGMP manufacturing facility.